-
Most Popular
Search Results
240 results for java
Bring a Neck Brace When Trading Cassava Sciences
Cassava is still pre-revenue but SAVA stock has a flock of strong fans. They bought the dip with gumption, which suggests long-term success.
SAVA Stock Alert: What Is Going on With Red-Hot Cassava Sciences Today?
Biotech company Cassava saw a big jump today on positive news related to its Alzheimer’s disease treatment. Keep an eye on SAVA stock.
Zoe’s Kitchen Stock Skyrockets on Takeover Deal
Zoe’s Kitchen (ZOES) stock was flying high Friday on news of a takeover deal that will have it being acquired by Cava Group.
Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations
SAVA stock is still one of the best performers this year, but the recent allegations mean shares will fall further as the story develops.
Cassava Sciences Looks Like It Will Be a Winner In Fighting Alzheimer’s
Cassava Sciences will likely be a winner in the fight against Alzheimer’s. If successful, SAVA stock is worth significantly more.
Keep Risk in Mind With Cassava Sciences Stock, but Don’t Dismiss Upside Potential
If you can stomach the risk and have experience investing in clinical stage biotech plays, SAVA stock remains an interesting situation. After its recent weakness,…
Cassava Sciences’ Stock Remains an Enigma
Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run. It did the…
Breaking Up Qualcomm Is Just Good Thinking (QCOM)
An activist investor’s call to split up the chip-making and patent-licensing businesses at Qualcomm would make QCOM a much better buy.
Keep an Eye on $60 as a Target Price for Cassava Sciences
As long as you’re using a moderate position size, it’s fine to hold SAVA stock as it has a tendency to move fast and far…
Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade
Take a wild ride — but keep your position size small, please — as SAVA stock could return to all-time highs or plummet to new…
Cassava Sciences Is in a Bleak Midwinter Waiting for Spring and Better Days
SAVA stock is driven by updates on clinical Phase 3 trials and lots of irrationality. Meanwhile, an FDA approval may take quite some time.
The Good News Is Piling Up for Cassava Stock
Recent news indicates that the FDA is going to reject a petition against Cassava, helping to make SAVA stock very attractive.
The Crowd Has Wisely Soured on Cassava Sciences Stock
As perceptions rise that its flagship drug candidate won’t make it to market, steer clear of SAVA stock.
While Cassava Sciences Is a Risky Play, It Has Substantial Payoff Potential
If you can stomach the volatility, you may want to enter an appropriately-sized position in SAVA stock.
CORZ Stock Alert: Core Scientific Rejects Takeover Offer From Coreweave
Core Scientific stock is up on Thursday after the Bitcoin mining company rejected an unsolicited takeover offer for CORZ from CoreWeave
Cassava Sciences Is a Worthwhile Bet to Consider
FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer’s disease could help propel SAVA stock back up.
Cassava Sciences Is Worth Considering After Hitting Its Latest Trough
The company has no debt and is cash rich. If it receives FDA approval for its Simufilam drug, the SAVA stock price will catapult.
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
LVTX stock results show that LAVA Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
SAVA Stock Alert: Former Cassava Science Advisor Charged With Fraud
SAVA stock is trading lower after a scientist behind Cassava’s simufilam was charged with manipulating research data to justify his grants.
Why Is Cassava Sciences (SAVA) Stock Up Today?
Today’s big move in Cassava Sciences and SAVA stock has many investors watching this company’s trials closer than ever.
10 – 10 of 240 results
